Martin Hirsch1, James M N Duffy2, Christine S Deguara3, Colin J Davis4, Khalid S Khan4. 1. Women's Health Research Unit, The Blizard Institute, Barts and the London School of Medicine and Dentistry, Yvonne Carter Building, 58 Turner Street, Whitechapel, London, E1 2AB, United Kingdom; Royal Free London NHS Trust, London, NW3 2QG, United Kingdom. Electronic address: m.hirsch@qmul.ac.uk. 2. Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, University of Oxford, Oxford, OX1 2JD, United Kingdom. 3. Centre for Reproductive Medicine, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, EC1A 7BE, United Kingdom. 4. Women's Health Research Unit, The Blizard Institute, Barts and the London School of Medicine and Dentistry, Yvonne Carter Building, 58 Turner Street, Whitechapel, London, E1 2AB, United Kingdom.
Abstract
STUDY OBJECTIVE: To assess the diagnostic accuracy of serum Cancer Antigen 125 (CA 125)≥30units/milliliter (u/ml) for diagnosing endometriosis in symptomatic women. STUDY DESIGN: Prospective observational cohort study including patients with symptoms of pelvic pain or subfertility undergoing elective diagnostic laparoscopy at two tertiary referral hospitals. We excluded patients suspected to have other gynecological pathology. We evaluated the accuracy of serum CA 125 (index test) with histologically confirmed endometriosis (reference standard). MAIN RESULTS: Fifty-eight consecutive women recruited between October 2013 to March 2015. Women with endometriosis had a higher CA 125 level than those without endometriosis (mean 54.7+/-71.6 vs 16.2+/- 8.0). The specificity of CA 125≥30u/ml was 96% (95% CI 81.7-99.9%) and sensitivity was 57% (95% CI 37.4-74.5%). The positive likelihood ratio for the histological presence of endometriosis with a CA 125≥30u/ml was 15.8 (95% CI 2.3-112) providing a post-test probability of 94% (95% CI 71%-99%) in women with pelvic pain or subfertility. The area under the curve, 0.85 (95% CI 0.74-0.96) indicates high test accuracy. CONCLUSIONS: CA 125≥30u/ml is highly predictive of endometriosis in women with symptoms of pain and/or subfertility. CA 125 should be considered as a rule-in test for expediting the diagnosis and management of endometriosis, CA 125 <30u/ml is, however, unable to rule out endometriosis.
STUDY OBJECTIVE: To assess the diagnostic accuracy of serum Cancer Antigen 125 (CA 125)≥30units/milliliter (u/ml) for diagnosing endometriosis in symptomatic women. STUDY DESIGN: Prospective observational cohort study including patients with symptoms of pelvic pain or subfertility undergoing elective diagnostic laparoscopy at two tertiary referral hospitals. We excluded patients suspected to have other gynecological pathology. We evaluated the accuracy of serum CA 125 (index test) with histologically confirmed endometriosis (reference standard). MAIN RESULTS: Fifty-eight consecutive women recruited between October 2013 to March 2015. Women with endometriosis had a higher CA 125 level than those without endometriosis (mean 54.7+/-71.6 vs 16.2+/- 8.0). The specificity of CA 125≥30u/ml was 96% (95% CI 81.7-99.9%) and sensitivity was 57% (95% CI 37.4-74.5%). The positive likelihood ratio for the histological presence of endometriosis with a CA 125≥30u/ml was 15.8 (95% CI 2.3-112) providing a post-test probability of 94% (95% CI 71%-99%) in women with pelvic pain or subfertility. The area under the curve, 0.85 (95% CI 0.74-0.96) indicates high test accuracy. CONCLUSIONS:CA 125≥30u/ml is highly predictive of endometriosis in women with symptoms of pain and/or subfertility. CA 125 should be considered as a rule-in test for expediting the diagnosis and management of endometriosis, CA 125 <30u/ml is, however, unable to rule out endometriosis.
Authors: Alexis D Greene; Jessica A Kendziorski; Jeanette M Buckholz; Liang Niu; Changchun Xie; Susan M Pinney; Katherine A Burns Journal: Reprod Toxicol Date: 2018-12-21 Impact factor: 3.143
Authors: Pietro G Signorile; Maria Cassano; Rosa Viceconte; Maria Spyrou; Valentina Marcattilj; Alfonso Baldi Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Christopher DeAngelo; Megan Burnett Tarasiewicz; Athena Strother; Heather Taggart; Caron Gray; Meaghan Shanahan; Christopher Glowacki; Jimmy Khandalavala; Erin Talaska; Andrea Kinnan; John Joseph Coté; Adrienne Perfilio Edwards; Gina Harper-Harrison; Murray Joseph Casey; Traci-Lynn Hirai; Sarah Schultz; Lynnea Stines; Roma Vora; Dominique Boudreau; Jennifer Burgart; Meredith Shama; Trevor Watson; Lisa Strasheim; Rachel Thompson; Rachel Lawlor; Kayleen Joyce; Claire M Magnuson; Jane Driano; Breanna Elger; Anne Lentino; Margaret Driscoll; Elise Tidwell; Apoorva Sharma; Sarah R Walker; Gretchen Jones; Poonam Sharma; Holly Stessman; Yanyuan Wu; Jay Vadgama; Dana Chase; Lesley Conrad; Srinivasa T Reddy; Robin Farias-Eisner Journal: J Cancer Res Ther Oncol Date: 2020-12-29
Authors: Liudmila M Mikhaleva; Aleksandr I Davydov; Olga I Patsap; Elizaveta V Mikhaylenko; Vladimir N Nikolenko; Margarita E Neganova; Sergey G Klochkov; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev Journal: Adv Ther Date: 2020-05-08 Impact factor: 3.845
Authors: Laura A Warren; Andrew Shih; Susana Marquez Renteira; Tamer Seckin; Brandon Blau; Kim Simpfendorfer; Annette Lee; Christine N Metz; Peter K Gregersen Journal: Mol Med Date: 2018-03-19 Impact factor: 6.354
Authors: Naoko Sasamoto; Mary DePari; Allison F Vitonis; Marc R Laufer; Stacey A Missmer; Amy L Shafrir; Kathryn L Terry Journal: PLoS One Date: 2020-08-24 Impact factor: 3.240